<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463226</url>
  </required_header>
  <id_info>
    <org_study_id>AnabolicHormonesPrognosis</org_study_id>
    <nct_id>NCT03463226</nct_id>
  </id_info>
  <brief_title>Effects of Hormonal Anabolic Deficiency and Neurovascular Alterations on Mortality in Male Patients With Heart Failure</brief_title>
  <acronym>TestoHF</acronym>
  <official_title>Hormonal Anabolic Deficiency Associated With Neurovascular Alterations Predict Poor Prognosis in Male Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) has been associated with chronic deleterious effects on skeletal muscle,&#xD;
      endocrine system, vasculature and sympathetic nervous system. These alterations have a&#xD;
      significant impact on quality of life, leading to a reduction in functional capacity and&#xD;
      limited symptoms, which involve dyspnea and fatigue. The investigators tested the hypothesis&#xD;
      that hormonal anabolic deficiency associated with neurovascular alterations may worsen the&#xD;
      prognosis of patients with heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred and fifty six patients have been enrolled so far. Methods were as described&#xD;
      below:&#xD;
&#xD;
        -  Muscle sympathetic nerve activity (MSNA) was directly recorded from the peroneal nerve&#xD;
           using the microneurography technique ;&#xD;
&#xD;
        -  All patients underwent symptom-limited cardiopulmonary exercise test performed on a&#xD;
           cycle ergometer, using a ramp protocol with workload increments of 5 or 10 Watts per&#xD;
           minute;&#xD;
&#xD;
        -  Body composition measurements were performed using dual-energy X-ray absorptiometry&#xD;
           (DXA);&#xD;
&#xD;
        -  Muscle strength was assessed by handgrip dynamometer using the mean value of three&#xD;
           attempts;&#xD;
&#xD;
        -  Blood samples were drawn in the morning after 12h overnight fasting. The laboratory&#xD;
           tests included B-type natriuretic peptide (BNP; pg/mL) plasma level, serum sodium&#xD;
           (mEq/L), serum potassium (mEq/L), creatinine (mg/dL), haemoglobin level (g/dL),&#xD;
           high-sensitivity C-reactive protein (CRP; mg/L), lipid profile (triglyceride, total&#xD;
           cholesterol, high-density lipoprotein, and low-density lipoprotein; mg/dL), and fasting&#xD;
           glucose (mg/dL). Blood sample to assess hormone plasma levels were also drawn at the&#xD;
           same time: total testosterone (TT), free testosterone (FT), sex hormone binding globulin&#xD;
           (SHBG), dehydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH),&#xD;
           follicle-stimulating hormone (FSH), thyroid stimulating hormone (TSH) and insulin-like&#xD;
           growth factor 1 (IGF1).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of testosterone deficiency on mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Blood sample was collected in the morning (between 8:00-10:00 a.m.) after 12 hours fasting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of muscle sympathetic nerve activity on mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Microneurography was used to assess the sympathetic nervous system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of neurovascular alterations on mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Venous occlusion pletysmography was used to evaluate vasodilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of testosterone deficiency on body composition</measure>
    <time_frame>2 years</time_frame>
    <description>Body composition measurements were performed using dual-energy X-ray absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of testosterone deficiency on functional capacity</measure>
    <time_frame>2 years</time_frame>
    <description>All patients underwent symptom-limited cardiopulmonary exercise test to measure functional capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of testosterone deficiency on strength</measure>
    <time_frame>2 years</time_frame>
    <description>Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">169</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Low testosterone</arm_group_label>
    <description>Patients with HF and testosterone deficiency.&#xD;
Cardiopulmonary exercise test&#xD;
Muscle Sympathetic Nerve Activity&#xD;
Dual-energy X-ray absorptiometry&#xD;
Venous occlusion plethysmography&#xD;
Blood sample collection&#xD;
Dynamometers for Handgrip Strength</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal testosterone</arm_group_label>
    <description>Patients with HF and normal plasma levels of testosterone.&#xD;
Cardiopulmonary exercise test&#xD;
Muscle Sympathetic Nerve Activity&#xD;
Dual-energy X-ray absorptiometry&#xD;
Venous occlusion plethysmography&#xD;
Blood sample collection&#xD;
Dynamometers for Handgrip Strength</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiopulmonary exercise test</intervention_name>
    <description>Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.</description>
    <arm_group_label>Low testosterone</arm_group_label>
    <arm_group_label>Normal testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Muscle Sympathetic Nerve Activity</intervention_name>
    <description>Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.</description>
    <arm_group_label>Low testosterone</arm_group_label>
    <arm_group_label>Normal testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dual-energy X-ray absorptiometry</intervention_name>
    <description>Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.</description>
    <arm_group_label>Low testosterone</arm_group_label>
    <arm_group_label>Normal testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Venous occlusion plethysmography</intervention_name>
    <description>Venous occlusion plethysmography was used to assess non-invasively blood flow.</description>
    <arm_group_label>Low testosterone</arm_group_label>
    <arm_group_label>Normal testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Blood samples were drawn in the morning after 12h overnight fasting.</description>
    <arm_group_label>Low testosterone</arm_group_label>
    <arm_group_label>Normal testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dynamometers for Handgrip Strength</intervention_name>
    <description>Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.</description>
    <arm_group_label>Low testosterone</arm_group_label>
    <arm_group_label>Normal testosterone</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure recruited at Clinical Unit of Myocardiopathy at General&#xD;
        Hospital of the University of São Paulo Medical School (UNCAR/HC-FMUSP).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 65 years old;&#xD;
&#xD;
          -  at least1 year of diagnosed HF;&#xD;
&#xD;
          -  left ventricular ejection fraction (LVEF) lower than 40% measured by echocardiography;&#xD;
&#xD;
          -  non-ischaemic and ischaemic aetiologies;&#xD;
&#xD;
          -  compensated HF with optimal medication for at least 3 months prior the study;&#xD;
&#xD;
          -  New York Heart Association (NYHA) class of I to IV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with autonomic diabetic neuropathy;&#xD;
&#xD;
          -  patients with chronic renal failure with haemodialysis;&#xD;
&#xD;
          -  heart transplantation;&#xD;
&#xD;
          -  presence of pacemaker;&#xD;
&#xD;
          -  patients with muscular dystrophy (i.e. Duchenne muscular dystrophy);&#xD;
&#xD;
          -  patients submitted to any hormonal treatment;&#xD;
&#xD;
          -  history of cancer;&#xD;
&#xD;
          -  ongoing infection;&#xD;
&#xD;
          -  myocardial infarction with percutaneous coronary intervention or revascularization 6&#xD;
             months prior to the study entry.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Janieire de Nazaré Nunes Alves, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto do Coração do Hospital da Clínicas da Universidade de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Maria Janieire de Nazaré Nunes Alves</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Testosterone Deficiency</keyword>
  <keyword>Sympathetic overactivity</keyword>
  <keyword>Exercise Intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

